Content reviewed by clinical research staff
Evidence graded using the PeptideScholar A-D system
Dulaglutide
AFDA ApprovedGLP-1 receptor agonist · 31 amino acids · Brand: Trulicity
Dulaglutide is a once-weekly GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Trulicity, 2014). It is a fusion protein consisting of two GLP-1 analog chains covalently linked to a modified human IgG4 Fc fragment, giving it a half-life of approximately 5 days.
Mechanism of Action
Activates GLP-1 receptors to stimulate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite. The Fc fusion extends half-life through reduced renal clearance and protection from degradation, enabling once-weekly dosing without complex formulation.
Benefits
- Once-weekly dosing with simple pen device
- Significant HbA1c reduction and moderate weight loss[1]
- Proven cardiovascular benefit (REWIND trial)
- Lower injection-site reaction rates vs some other GLP-1s
Side Effects
- Nausea, vomiting, diarrhea (GI class effects)
- Decreased appetite
- Hypoglycemia when combined with insulin or sulfonylureas
- Pancreatitis (rare, class warning)
- Thyroid C-cell tumor risk (animal data, class warning)
Ready to Discuss Dulaglutide with a Doctor?
Dulaglutide is FDA-approved and available by prescription. Licensed telehealth providers can evaluate if it's right for you.
Find a Prescribing ProviderTelehealth consultations available in most states
PeptideScholar may receive compensation from provider referrals. This does not influence our editorial content.
Dulaglutide in PeptideScholar's current approved-treatment dataset
Dulaglutide is currently modeled on this site as an approved treatment path for: Type 2 diabetes mellitus; cardiovascular risk reduction in adults with T2D and established CV disease or multiple risk factors. Brand names in the current dataset: Trulicity.
Research & Evidence
Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
Dulaglutide 1.5 mg was non-inferior to liraglutide 1.8 mg for HbA1c reduction, with comparable weight loss and a favorable GI tolerability profile
PMID: 25018121References
- 1. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.. Lancet, 2014. “Dulaglutide 1.5 mg was non-inferior to liraglutide 1.8 mg for HbA1c reduction, with comparable weight loss and a favorable GI tolerability profile” [PMID: 25018121]
Recommended Resources
The Peptide Protocols Handbook
Evidence-based reference guide covering mechanisms, research, and clinical applications.
View on AmazonThird-Party Peptide Testing
Independent lab analysis to verify peptide purity and authenticity.
Learn MoreLinks may be affiliate links. See our disclosure.
GLP-1 Support Essentials
Products to help manage side effects and optimize outcomes during treatment.
LMNT Electrolyte Packets
Sodium-focused electrolytes to prevent dehydration and fatigue common in early GLP-1 therapy.
High-Protein Shakes (30g)
Convenient protein shakes to maintain muscle mass on reduced GLP-1 caloric intake.
Metamucil Fiber Supplement
Soluble fiber powder to manage constipation and GI side effects during GLP-1 treatment.
Vitamin B12 (Methylcobalamin 1000mcg)
GLP-1 agonists can reduce B12 absorption over time — methylcobalamin is the most bioavailable form.
Ginger Chews for Nausea
Natural nausea relief for the dose-escalation adjustment period, particularly weeks 1–4.
Unflavored Whey Protein Isolate
Preserve lean mass without excess carbs or calories when appetite is suppressed.
Amazon affiliate links — we may earn a small commission at no extra cost to you. See our disclosure.
Progress Tracking Tools
Monitor weight, body composition, and nutrition to maximize results.
Smart WiFi Body Scale
Tracks BMI, body fat %, and muscle mass — essential for monitoring GLP-1 progress over time.
Digital Kitchen Food Scale
Precise gram-level portion tracking helps maximize weight loss results on GLP-1 therapy.
Protein Shaker Bottle Set
Leak-proof mixing bottles for protein shakes — supports consistent protein intake on a smaller appetite.
Amazon affiliate links — we may earn a small commission at no extra cost to you. See our disclosure.
Recommended Reading
Books covering peptide science, longevity research, and biohacking frameworks.
The Peptide Protocols
Comprehensive reference for peptide mechanisms, dosing research, and clinical applications.
Boundless by Ben Greenfield
Covers peptides, nootropics, hormones, and longevity strategies in an optimization framework.
Lifespan by David Sinclair
Evidence-based deep-dive into aging science, directly relevant to longevity peptide research.
The Longevity Paradox
Gut-centric aging research with diet and supplementation protocols for extending healthspan.
Amazon affiliate links — we may earn a small commission at no extra cost to you. See our disclosure.
Dulaglutide FAQ
Medical Disclaimer
This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.
Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.
No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.
Related Peptides
Semaglutide
ASemaglutide is a GLP-1 receptor agonist approved by the FDA for type 2 diabetes ...
Liraglutide
ALiraglutide is a GLP-1 receptor agonist approved by the FDA for type 2 diabetes ...
Exenatide
AExenatide is a GLP-1 receptor agonist and the first incretin mimetic approved by...
Pramlintide
APramlintide is a synthetic analog of human amylin, a pancreatic beta-cell hormon...
Get peptide research updates
Weekly evidence summaries and regulatory alerts.
No spam. Unsubscribe anytime.